Campbell & Co Investment Adviser’s Acadia Pharmaceuticals ACAD Stock Holding History

Campbell & Co Investment Adviser’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-39,286	Closed	-$838K	–	1099
2025 Q3	$838K	Buy	+39,286	New	+$929K	0.06%	490
2024 Q3	–	Sell	-36,122	Closed	-$587K	–	1058
2024 Q2	$587K	Buy	+36,122	New	+$583K	0.05%	593
2024 Q1	–	Sell	-67,342	Closed	-$2.11M	–	1070
2023 Q4	$2.11M	Buy	+67,342	New	+$1.61M	0.19%	119
2023 Q3	–	Sell	-15,619	Closed	-$374K	–	907
2023 Q2	$374K	Buy	+15,619	New	+$347K	0.07%	566
2021 Q4	–	Sell	-15,250	Closed	-$253K	–	596
2021 Q3	$253K	Buy	+15,250	New	+$294K	0.08%	434
2020 Q3	–	Sell	-4,581	Closed	-$222K	–	371
2020 Q2	$222K	Buy	+4,581	New	+$220K	0.28%	185
2020 Q1	–	Sell	-5,040	Closed	-$216K	–	22
2019 Q4	$216K	Sell	5,040 -11,153	-69%	-$485K	0.07%	558
2019 Q3	$583K	Buy	+16,193	New	+$491K	0.22%	136
2017 Q3	–	Sell	-9,817	Closed	-$274K	–	337
2017 Q2	$274K	Buy	+9,817	New	+$293K	0.25%	163

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Campbell & Co Investment Adviser's ACAD Position: Q4 2025 in Review

Campbell & Co Investment Adviser sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 39,286 shares — an estimated $838K sold.

Campbell & Co Investment Adviser first reported a position in ACAD in Q2 2017 and held it in 9 quarters. The position peaked at $2.11M in Q4 2023. 334 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

Campbell & Co Investment Adviser reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Campbell & Co Investment Adviser sold 39,286 Acadia Pharmaceuticals shares in Q4 2025, an estimated $838K.
Campbell & Co Investment Adviser first reported a position in Acadia Pharmaceuticals in Q2 2017 and held it in 9 quarters.
Campbell & Co Investment Adviser's Acadia Pharmaceuticals position peaked at $2.11M in Q4 2023.
334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2025, filed 12 Feb 2026.